Cardiovascular diseases (CVD) remain the leading cause of disease burden , causing one in three deaths worldwide as a result of population growth, population aging and exposure to a broad range of ...

The ketogenic or “keto” diet, which involves consuming very low amounts of carbohydrates and high amounts of fats, has been gaining popularity. However, a new study presented at the American College ...

The Young Investigator Awards competition provides young scientific investigators with an opportunity to showcase their cutting-edge research. At ACC.27-WCC, 15 finalists will present their work in ...

Inflammation plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease. 1 Atherosclerosis in particular is an inflammatory process that involves endothelial dysfunction, ...

Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction and their broader impacts on cardiometabolic health beyond ...

A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the ...

In-hospital initiation of dapagliflozin in patients hospitalized for acute heart failure (HF) did not significantly reduce the short-term risk of worsening HF or death, based on findings from the DAPA ...

In the ABYSS (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization) trial, interruption of ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

The ACC is dedicated to creating a strong, diverse and inclusive field of future cardiovascular physicians, scientists and professionals. The ACC's Internal Medicine and Pediatric Cardiology Program ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...